High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF
exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10).
This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy
and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the
treatment of PCTB.